Nkarta (NKTX) Competitors $2.37 +0.05 (+2.16%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.42 +0.05 (+2.15%) As of 08/22/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKTX vs. MRVI, KROS, BCAX, RLAY, TYRA, SAGE, UPXI, TRML, TERN, and RAPPShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Maravai LifeSciences (MRVI), Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), Sage Therapeutics (SAGE), Upexi (UPXI), Tourmaline Bio (TRML), Terns Pharmaceuticals (TERN), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Its Competitors Maravai LifeSciences Keros Therapeutics Bicara Therapeutics Relay Therapeutics Tyra Biosciences Sage Therapeutics Upexi Tourmaline Bio Terns Pharmaceuticals Rapport Therapeutics Maravai LifeSciences (NASDAQ:MRVI) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends. Does the media favor MRVI or NKTX? In the previous week, Nkarta had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 8 mentions for Nkarta and 5 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 1.15 beat Nkarta's score of 0.18 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nkarta 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, MRVI or NKTX? Maravai LifeSciences has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Nkarta has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Do analysts rate MRVI or NKTX? Maravai LifeSciences currently has a consensus price target of $5.75, suggesting a potential upside of 134.69%. Nkarta has a consensus price target of $13.60, suggesting a potential upside of 473.84%. Given Nkarta's stronger consensus rating and higher probable upside, analysts clearly believe Nkarta is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25Nkarta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, MRVI or NKTX? Nkarta has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$219.83M2.84-$144.85M-$1.36-1.80NkartaN/AN/A-$108.79M-$1.48-1.60 Is MRVI or NKTX more profitable? Nkarta has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -90.03%. Maravai LifeSciences' return on equity of -17.60% beat Nkarta's return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-90.03% -17.60% -9.30% Nkarta N/A -27.74%-22.38% Do institutionals & insiders believe in MRVI or NKTX? 50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 2.1% of Maravai LifeSciences shares are held by company insiders. Comparatively, 8.4% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryNkarta beats Maravai LifeSciences on 11 of the 16 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$164.78M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-1.6020.8831.1026.04Price / SalesN/A343.33433.45102.77Price / CashN/A43.1937.7358.48Price / Book0.478.129.536.61Net Income-$108.79M-$54.72M$3.26B$265.56M7 Day Performance1.72%2.63%2.10%1.97%1 Month Performance6.28%2.78%2.81%-0.36%1 Year Performance-55.45%11.01%30.56%19.03% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta2.0327 of 5 stars$2.37+2.2%$13.60+473.8%-54.0%$164.78MN/A-1.60140MRVIMaravai LifeSciences4.0374 of 5 stars$2.06-6.4%$6.64+222.3%-72.3%$560.25M$259.18M-1.81610Options VolumeGap UpKROSKeros Therapeutics3.0349 of 5 stars$13.35-2.8%$30.00+124.7%-65.2%$557.65M$3.55M43.07100News CoverageBCAXBicara Therapeutics1.6366 of 5 stars$9.99-2.1%$31.86+218.9%N/A$556.27MN/A0.0032Analyst ForecastRLAYRelay Therapeutics1.9971 of 5 stars$3.25+0.9%$17.25+430.8%-46.8%$555.16M$10.01M-1.67330TYRATyra Biosciences2.3132 of 5 stars$10.10-3.3%$30.83+205.3%-46.2%$554.79MN/A-6.2020News CoverageAnalyst ForecastSAGESage Therapeutics3.4282 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690UPXIUpexi2.7902 of 5 stars$5.62-7.0%$15.50+175.8%+107.5%$539.74M$26M0.00130TRMLTourmaline Bio2.3767 of 5 stars$20.99+1.3%$49.33+135.0%+63.7%$532.20MN/A-6.5444TERNTerns Pharmaceuticals3.7712 of 5 stars$6.30+3.6%$15.63+148.0%-11.9%$532.07MN/A-6.0640RAPPRapport Therapeutics1.7486 of 5 stars$14.34-1.4%$29.50+105.7%-30.4%$531.04MN/A-5.74N/A Related Companies and Tools Related Companies Maravai LifeSciences Competitors Keros Therapeutics Competitors Bicara Therapeutics Competitors Relay Therapeutics Competitors Tyra Biosciences Competitors Sage Therapeutics Competitors Upexi Competitors Tourmaline Bio Competitors Terns Pharmaceuticals Competitors Rapport Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NKTX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access